Biodel, Aegis sign licensing agreement for ProTek, Intravail technologies

According to the agreement, a variety of glucagon presentations will be developed and commercialized including Biodel’s glucagon product candidate, a liquid formulation in an auto injector intended for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

The agreement also considers including the use of glucagon in the treatment of hyperinsulinemia with continuous subcutaneous infusion and the treatment of hypoglycemia via intranasal administration and administration via a bi-hormonal pump.

Biodel chief executive officer Errol De Souza said the glucagon program addresses an important unmet medical need, the lack of a convenient, user friendly treatment for severe hypoglycemia, while significantly strengthening our pipeline.

ProTek protein stabilization technology consists of the use of GRAS excipients that prevent aggregation of proteins and peptides thereby improving the stability of drug product formulated with these excipients.

Intravail consists of a class of transmucosal absorption enhancement agents that allow non-invasive systemic delivery of potent peptide, protein, nucleotide-related, and other small and large molecule drugs.

Accelerated stability data specify that ProTek-based glucagon formulations have greater physical and chemical stability than existing commercial formulations following reconstitution.